Έχω ψάξει το φόρουμ κ δεν βρήκα κάτι για το παρακάτω...είπα λοιπόν να το ποστάρω ...
http://www.regrowth.com/hairloss-remedy/neosh101/neosh101-phase2a.cfm
Neosil Announces Positive Phase 2 Data for NEOSH101, an Investigational Treatment for Androgenetic Alopecia
EMERYVILLE, CA -- January 04, 2007 -- Just when you think there's nothing new in the world of hairloss, along comes a new player ready to shake things up. Neosil, Inc., a privately held pharmaceutical company, has announced the results of a study on a new topical hairloss treatment, NEOSH101.
When I read the first paragraph of the press release, I was somewhat skeptical -- then I saw doctors such as Vera Price were involved and my level of interest went way up.
Vera H. Price, MD, FRCP(C) is a Professor of Clinical Dermatology for the Department of Dermatology at the University of California, San Francisco. She has been involved in studying almost every major treatment for hairloss available, from Rogaine to Propecia and many others and is an acknowledged expert in the field. I've had the pleasure of meeting Dr. Price a couple of times before at conferences -- when Dr. Price presents information about a new hairloss treatment, you get facts and statistics, not conjecture.
"Based on the results of this study, we are quite encouraged by the increase in hair growth observed after such a short once-daily treatment regimen with NEOSH101," said Dr. Price.
The study was a randomized, double blind Phase 2a clinical study consisting of 50 men in Germany with hairloss between Norwood/Hamilton grades III-IV. The men received topical treatments of NEOSH101 or placebo once a day for two 14-day treatment periods that were separated by one month of no treatment.
Using a photographic, computer-based analysis, hair growth was measured for up to 24 weeks after the start of the treatment. The initial results showed that NEOSH101 was safe and well tolerated. The analysis showed a statistically significant increase in the total hair count and the thickness of the hairs with the greatest effects seen eight weeks after the second treatment cycle.
The Vice President of Clinical Development at Neosil, Andria Langenberg, M.D., said "The results of this study are encouraging, particularly the finding of increased numbers of terminal hairs, those hairs that are thicker than 40 microns and desirable for scalp coverage... We plan to initiate a Phase 2b study to evaluate daily treatment with NEOSH101 for a longer treatment period in men with PHL."
Regrowth is in the process of contacting Noesil's representatives for a more in-depth interview and findings regarding this new treatment. We expect to have more information soon.
http://www.regrowth.com/hairloss-remedy/neosh101/neosh101-phase2a.cfm
Neosil Announces Positive Phase 2 Data for NEOSH101, an Investigational Treatment for Androgenetic Alopecia
EMERYVILLE, CA -- January 04, 2007 -- Just when you think there's nothing new in the world of hairloss, along comes a new player ready to shake things up. Neosil, Inc., a privately held pharmaceutical company, has announced the results of a study on a new topical hairloss treatment, NEOSH101.
When I read the first paragraph of the press release, I was somewhat skeptical -- then I saw doctors such as Vera Price were involved and my level of interest went way up.
Vera H. Price, MD, FRCP(C) is a Professor of Clinical Dermatology for the Department of Dermatology at the University of California, San Francisco. She has been involved in studying almost every major treatment for hairloss available, from Rogaine to Propecia and many others and is an acknowledged expert in the field. I've had the pleasure of meeting Dr. Price a couple of times before at conferences -- when Dr. Price presents information about a new hairloss treatment, you get facts and statistics, not conjecture.
"Based on the results of this study, we are quite encouraged by the increase in hair growth observed after such a short once-daily treatment regimen with NEOSH101," said Dr. Price.
The study was a randomized, double blind Phase 2a clinical study consisting of 50 men in Germany with hairloss between Norwood/Hamilton grades III-IV. The men received topical treatments of NEOSH101 or placebo once a day for two 14-day treatment periods that were separated by one month of no treatment.
Using a photographic, computer-based analysis, hair growth was measured for up to 24 weeks after the start of the treatment. The initial results showed that NEOSH101 was safe and well tolerated. The analysis showed a statistically significant increase in the total hair count and the thickness of the hairs with the greatest effects seen eight weeks after the second treatment cycle.
The Vice President of Clinical Development at Neosil, Andria Langenberg, M.D., said "The results of this study are encouraging, particularly the finding of increased numbers of terminal hairs, those hairs that are thicker than 40 microns and desirable for scalp coverage... We plan to initiate a Phase 2b study to evaluate daily treatment with NEOSH101 for a longer treatment period in men with PHL."
Regrowth is in the process of contacting Noesil's representatives for a more in-depth interview and findings regarding this new treatment. We expect to have more information soon.
